Regenxbio Inc RGNX.OQ RGNX.O is expected to show a rise in quarterly revenue when it reports results on March 13 for the period ending December 31 2024
The Rockville Maryland-based company is expected to report a 6.9% increase in revenue to $23.754 million from $22.21 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Regenxbio Inc is for a loss of $1.15 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Regenxbio Inc is $28.50, above its last closing price of $6.01.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.11 | -1.12 | -1.17 | Missed | -4.3 |
Jun. 30 2024 | -1.30 | -1.29 | -1.05 | Beat | 18.7 |
Mar. 31 2024 | -1.29 | -1.26 | -1.33 | Missed | -5.6 |
Dec. 31 2023 | -1.30 | -1.27 | -1.43 | Missed | -12.5 |
Sep. 30 2023 | -1.56 | -1.52 | -1.41 | Beat | 7.1 |
Jun. 30 2023 | -1.43 | -1.38 | -1.66 | Missed | -19.9 |
Mar. 31 2023 | -1.60 | -1.54 | -1.53 | Beat | 0.4 |
Dec. 31 2022 | -1.24 | -1.23 | -1.38 | Missed | -11.8 |
This summary was machine generated March 11 at 20:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。